RxDoctor Payments Data

Yasir Elamin, MD

Psychiatry · Reston, VANPI 1003945346

Payments from drug & device makers

$2,247in general payments, 2019–2025

Across 104 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$551
  • Alkermes, Inc.$397
  • Sunovion Pharmaceuticals Inc.$308
  • Otsuka America Pharmaceutical, Inc.$236
  • Teva Pharmaceuticals USA, Inc.$233
  • AbbVie$156
  • plus $366 from 7 others

What the payments were for

  • Food & beverage$2,21398%
  • Education$342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,247 in reported general payments places this provider in the 80th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$26,051
Medicare patients
24
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate59$178,736
Abilify MaintenaAripiprazole30$89,829
FanaptIloperidone14$31,378
SuboxoneBuprenorphine Hcl/Naloxone Hcl373$9,271
Aripiprazole164$6,040
Clozapine66$5,891
Paliperidone ErPaliperidone15$1,408
Divalproex Sodium ErDivalproex Sodium34$1,330
Olanzapine51$1,266
Clomipramine Hcl25$1,094
Gabapentin186$1,005
Quetiapine Fumarate66$882
Sertraline Hcl232$814
Duloxetine Hcl30$660
Trazodone Hcl50$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$551$178,73659 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$236$89,82930 claims
Vanda Pharmaceuticals Inc.Fanapt$120$31,37814 claims
Indivior Inc.Suboxone$26$9,271373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Reston

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →